A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Thyroid Eye Disease

In brief

The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.

Key facts

Study ID
NCT06401044
Run by
Amgen
People needed
88
Starts
2024-05-30
Expected to finish
2027-08-13
Last updated by the study team
2026-07-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.